DJ
Therapeutic Areas
CRISPR Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CASGEVY (exagamglogene autotemcel/exa-cel) | Sickle Cell Disease (SCD) | Approved |
| CTX110 (brontictabtagene autoleucel) | CD19+ B-cell malignancies (Large B-Cell Lymphoma) | Phase 1 |
| CTX130 (pradlocabtagene autoleucel) | CD70+ solid tumors (Renal Cell Carcinoma) & hematologic malignancies | Phase 1 |
| CTX112 | Autoimmune Diseases (e.g., Lupus) | Preclinical |
| CTX131 | Solid Tumors | Preclinical |
| VCTX210 (Vertex collab.) | Type 1 Diabetes | Phase 1/2 |
| CTX310 (Bayer collab.) | Cardiovascular Disease (e.g., ATTR amyloidosis) | Preclinical |
| CTX320 (Bayer collab.) | CNS Diseases (e.g., Alzheimer's) | Preclinical |
Leadership Team at CRISPR Therapeutics
DS
Dr. Samarth Kulkarni, Ph.D.
Chief Executive Officer and Chairman of the Board
DP
Dr. Phuong Khanh (P.K.) Morrow, M.D., FACP
Chief Medical Officer
MJ
Michael J. Tomsicek, CPA
Chief Financial Officer
DT
Dr. Tony Ho, M.D.
Executive Vice President, Head of Research & Development
BS
Brendan Smith
Chief Commercial Officer
DE
Dr. Emmanuelle Charpentier, Ph.D.
Founder and Member of the Board of Directors
DR
Dr. Rodger Novak, M.D.
Co-Founder and Member of the Board of Directors
DJ
Dr. John Leonard, M.D.
Member of the Board of Directors
DS
Dr. Shaun Foy
Co-Founder (former role)